参桃软肝丸方合羟基喜树碱介入治疗大肝癌的预后因素分析  

Analysis on the Prognostic Factors in Patients with Large Hepatocarcinoma Treated by Shentao Ruangan Pill and Hydroxycamptothecine

作　　者：林丽珠[1] 周岱翰[1] 刘琨[1] 王芳军[1] 蓝韶清[1] 叶小卫[1] 

机构地区：[1]广州中医药大学第一附属医院肿瘤中心,广州510407

出　　处：《中国中西医结合杂志》2005年第1期8-11,共4页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：国家中医药管理局资助 (No.0 0 - 0 1LP1 5)

摘　　要：目的观察口服参桃软肝丸合羟基喜树碱 (Hydroxycamptothecine ,HCPT)介入治疗 5 2例中晚期大肝癌的临床疗效 ,分析影响大肝癌预后的相关因素。方法 85例患者随机分为治疗组 5 2例与对照组33例 ,治疗组口服参桃软肝丸方合肝动脉插管局部灌注HCPT ;对照组以肝癌介入的常规疗法经导管动脉内化疗栓塞 (transcatheterarterialchemoembolization ,TACE)作为标准对照。从瘤体变化评价两组的临床疗效 ,用Cox比例风险模型进行预后因素分析 ,采用Kaplan Meier法进行生存分析。结果 (1)治疗组瘤体有效率为 19 2 % ,稳定率为 82 7% ,对照组分别为 2 1 2 % ,81 8% ,两组比较差异无显著性 (P >0 0 5 ) ;(2 )中位生存期治疗组为 32 6天 ,对照组为 2 6 2天。 0 5年、1年及 2年生存率治疗组分别为 80 95 % ,4 1 39% ,12 4 2 % ,对照组分别为 6 4 2 9% ,2 5 0 0 %及 8 33% ,两组比较差异有显著性 (P <0 0 5 ) ;(3) 3种中医辨证分型中肝盛脾虚型与肝热血瘀型在生存期、生存率方面疗效相当 ,差异无显著性 (P >0 0 5 ) ,但与肝肾阴虚型比较 ,差异有显著性 (P <0 0 5 ) ;(4)影响预后的有利因素为治疗方法 ,治疗组优于对照组 (P <0 0 5 )。影响预后的危险因素有中医分型、临床分期及肝功能。肝盛脾虚型预后最好 。ObjectiveTo observe the effect of intervention therapy with Shentao Ruangan pill (SRP) and hydroxycamptothecine (HCPT) in treating 85 patients with middle advanced large hepatocarcinoma, and to analyze the factors that could affect the prognosis. MethodsEighty five patients were randomly divided into the treated group (n=52) and the control group (n=33). The treated group was treated by oral taking of SRP combined with local perfusion of HCPT through hepatic artery catheterization, while to the control group, the conventional therapy, transcatheter arterial chemoembolization (TACE) was conducted for control. The clinical efficacy of treatment in the two groups was evaluated by the change of tumor size, the factors related with prognosis were analyzed using Cox proportional hazards model and the analysis of survival conducted by Kaplan Meier method. Results(1) The tumor size reducing rate in the treated group was 19 2% and the tumor size stabilizing rate was 82 7%, while those in the control group was 21 2% and 81 8% respectively, comparison of the criteria between the two groups showed insignificant difference (P>0 05); (2) The median survival time, 0 5- year, 1- year and 2- year survival rate in the treated group was 326 days, 80 95%, 41 39% and 12 42% respectively, those in the control group was 262 days, 64 29%, 25 00% and 8 33% respectively, comparison between the two groups showed significant difference (P<0 05) ; (3) Among the 3 TCM types in patients, the survival time and rates in patients of Gan excess with Pi deficiency type was similar to those in patients of Gan heat with blood stasis type showing insignificant difference (P>0 05), but as compared with those in patients of Gan Shen Yin deficiency type, the difference was significant (P<0 05) ; (4) Beneficial factor to the prognosis were therapeutic method, that used in the treated group was superior to that used in the control group. The risk factors to the prognosis were TCM type, clinical stage and liver function. Patients of

关 键 词：大肝癌 对照组 治疗组 参桃软肝丸 预后 介入治疗 HCPT 显著性 差异 结论 

分 类 号：R735.7[医药卫生—肿瘤]